PATENT CLAIM ANALYSIS

Application Number: 15994934
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to a method for treating degenerative neurological disorders in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an acid sphingomyelinase (ASM) activity inhibitor or expression inhibitor as an active ingredient.

Claim (Index 4):
The method of  claim 1 , wherein the degenerative neurological disorder is at least one selected from a group consisting of Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, olivopontocerebellar atrophy (OPCA), Shy-Drager syndrome, Striatonigral degeneration, Huntington's disease, Amyotrophic lateral sclerosis (ALS), essential tremor, cortico-basal ganglionic degeneration, diffuse Lewy body disease, Parkinson-ALS-dementia complex of Guam, Pick's disease, ischemia, and cerebral infarction.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 93.0
- Lexical Diversity: 1.34211
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14889293', '15417315', '15313642', '14550025', '14289996']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7760387501706064
- 35 USC 102 Novelty (BERT): 0.612905922544135
- Combined Prediction Score: 0.7597254674079592
- Mean Citation Score: 350.576054
- Max Citation Score: 522.7991
- Similarity Product: 513.9338165374338

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test